Skip to main content

Table 1 A list of metabolites included in the metabolic profiling of the present study

From: Metabolic profiling reveals therapeutic effects of Herba Cistanches in an animal model of hydrocortisone-induced 'kidney-deficiency syndrome'

Compounds M/H/0 D/H/0 M/H/3 D/H/3 kw (P) corr coeffs M/H/10 D/H/10
Tyramine 1.1 1.1 2.8 2.8 0.0074 0.66 2.1 1.2
Dopamine -1.5 1.0 3.0 2.8 0.0045 0.88 1.7 1.4
Tetradecanoic acid 1.2 1.2 3.0 3.0 0.0045 0.65 3.0 1.0
Glycine 1.4 -1.3 2.8 2.1 0.0074 0.77 1.6 1.3
Galacturonic acid 1.4 1.3 3.0 3.0 0.0045 0.88 1.8 1.5
Hexadecanoic acid -1.0 1.2 2.2 2.5 0.0118 0.58 2.1 1.0
Acetate -1.4 -1.3 -3.0 -3.0 0.0045 -0.71 -2.6 -1.1
Uridine 1.4 1.4 2.5 1.3 0.0045 0.67 1.8 1.1
Oleic acid -1.1 -1.1 2.2 -1.1 0.0118 0.67 1.2 1.8
3-Hydroxyproline -1.1 1.0 2.0 1.6 0.0284 0.64 2.9 1.3
Octadecanoic acid 1.3 -1.3 2.5 2.5 0.0045 0.79 1.8 1.1
Noradrenaline -1.4 -1.3 2.5 1.0 0.0045 0.77 2.8 1.1
Alanine 1.0 1.0 2.5 2.2 0.0045 0.67 1.5 1.0
Gulonate -1.1 1.2 1.9 1.3 0.0424 0.53 2.8 1.4
4-(3-Hydroxy-phenyl)-butyric acid 1.2 1.3 2.1 -1.7 0.0424 0.86 1.1 1.1
2-Monopalmitin -1.3 -1.3 2.5 2.4 0.0045 0.73 1.2 1.2
1-Monoeleoylglycerol 1.1 1.1 -1.9 1.6 0.2912 0.6 -1.3 -1.3
Cholesterol 1.3 1.3 2.5 2.5 0.0045 0.62 1.7 1.0
Butanoic acid 1.1 -1.2 3.0 3.0 0.0045 0.83 1.9 1.1
D-galactose -1.4 -1.4 -1.8 -1.8 0.0618 -0.6 -1.3 -1.3
Stearin -1.0 1.2 -1.3 -1.6 0.4649 0.52 -1.4 -1.5
Eicosanoic acid -1.0 1.1 1.8 1.9 0.0618 0.85 1.4 1.1
Tyrosine 1.3 -1.0 2.8 1.2 0.0074 0.88 2.3 1.4
  1. Note: The correlation coefficients (corr coeffs) of all compounds were calculated from a cross-validated PLS-DA model (Q2Ycum = 0.899, a satisfactory model using two components) on day 3 between the control group and model group with or without Herba Cistanches treatment. Additionally, the fold changes were tested by the nonparametric Kruskal-Wallis test. Kw (P) denotes the P values of the test. H = control group, M = model group, D = treatment group. For example, H/M/0 represents the relative fold changes (model to control) at the pre-dose state.